Joyce Balls-Berry on Diversity: FDA Guidance and New Data on Incidence/Biomarkers by Race
COMMENT Another consideration in improving trial diversity is social and structural determinants to health that impact early screening and diagnosis of patients who are historically minoritized. A consideration is the patient's access to appropriate and qual